<SEC-DOCUMENT>0001193125-18-106513.txt : 20180404
<SEC-HEADER>0001193125-18-106513.hdr.sgml : 20180404
<ACCEPTANCE-DATETIME>20180403200232
ACCESSION NUMBER:		0001193125-18-106513
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180403
FILED AS OF DATE:		20180404
DATE AS OF CHANGE:		20180403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		18735548

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d563349d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated April&nbsp;3, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;&#9746; Form
40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Operational Update</B></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April&nbsp;3, 2018 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d563349dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g563349g45a33.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3&nbsp;April 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Operational Update </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">First two patients of the additional cohort of the Phase I, <FONT STYLE="white-space:nowrap">TACTI-mel</FONT> trial have commenced treatment; data to be reported <FONT STYLE="white-space:nowrap">mid-2018</FONT>
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AIPAC trial: 33 out of a planned 34 clinical sites now active with full recruitment expected in <FONT STYLE="white-space:nowrap">mid-2018</FONT> (Q3) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Six patients recruited for investigator-initiated Phase I trial, INSIGHT </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Preparations for new Phase II clinical trial program, <FONT STYLE="white-space:nowrap">TACTI-002</FONT> underway, with trial expected to commence in the second half of calendar 2018 </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA&#151;Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or the &#147;Company&#148;), provides an operational update on the
Company&#146;s ongoing development activities for its lead product candidates, eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), and IMP761, along with partner updates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Efti Clinical Update </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first two out of six patients
of the additional cohort of the Company&#146;s <FONT STYLE="white-space:nowrap">TACTI-mel</FONT> (<U>T</U>wo <U>ACT</U>ive <U>I</U>mmunotherapeutics in <U>mel</U>anoma) Phase I clinical trial in Australia have commenced their treatment. This follows
the recruitment of all 18 patients in the initial three cohorts of <FONT STYLE="white-space:nowrap">TACTI-mel</FONT> and the subsequent expansion of the trial to include an additional cohort of six patients in February 2018. The <FONT
STYLE="white-space:nowrap">TACTI-mel</FONT> trial evaluates the combination of efti and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy
KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) in unresectable or metastatic melanoma patients, with the additional cohort receiving 30mg of efti in combination with pembrolizumab starting at cycle one of
pembrolizumab. The Company plans to present data from the <FONT STYLE="white-space:nowrap">TACTI-mel</FONT> trial in the middle of this calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
the AIPAC (<U>A</U>ctive <U>I</U>mmunotherapy <U>PAC</U>litaxel) clinical trial, 33 out of a planned 34 clinical sites across Belgium, the Netherlands, Poland, Hungary, United Kingdom, France and Germany are now actively recruiting and treating
patients. The trial evaluates efti in combination with paclitaxel in metastatic breast cancer. The study remains on track to be to be fully recruited with 226 patients in Q3 of calendar year 2018; first Progression Free Survival data are expected in
calendar year 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Six patients have now been recruited for the investigator-initiated Phase I clinical trial INSIGHT, which is being conducted in
Frankfurt, Germany. These patients are receiving escalating doses of efti either via local (intratumoral) or loco-regional (intraperitoneal) injection. The objective of the study is to determine the recommended dose for each administration route for
an intended Phase II clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Company&#146;s announcement on 12&nbsp;March 2018 of its collaboration and supply agreement with
Merck&nbsp;&amp; Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of Immutep&#146;s lead immunotherapy product candidate, efti with MSD&#146;s <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab), Immutep is preparing to start its new clinical trial program <FONT
STYLE="white-space:nowrap">TACTI-002</FONT> (Two ACTive Immunotherapies) in the second half of calendar 2018. This new trial will evaluate the combination of efti with KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in patients
with advanced <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, head and neck cancer, or ovarian cancer. The Company plans to file the respective Investigational New Drug application (IND) with the U.S. Food and Drug Administration
(FDA) in the first half of calendar 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g563349g87t13.gif" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g563349g45a33.gif" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IMP761 Update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s IMP761 (a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">LAG-3-specific</FONT></FONT> antibody with unique agonistic
properties) is currently being tested in vivo in animal models. IMP761 is the first known therapeutic agonist <FONT STYLE="white-space:nowrap">LAG-3</FONT> antibody. To our knowledge, no other company has developed a therapeutic agonist antibody to
one of the three main immune checkpoint molecules, namely <FONT STYLE="white-space:nowrap">CTLA-4,</FONT> <FONT STYLE="white-space:nowrap">PD-1</FONT> and <FONT STYLE="white-space:nowrap">LAG-3,</FONT> as an immuno-suppressive drug for auto-immune
diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Efti Partnering Update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>EOC Pharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Immutep&#146;s
Chinese partner for efti, EOC Pharma, an oncology focused affiliate of Eddingpharm, received approval for the IND status in China and is expected to start clinical development in China with efti in H1 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>CYTLIMIC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Immutep is also
pleased to report that its partner CYTLIMIC has started a Phase I clinical trial for adjuvant immunotherapy at the Yamaguchi University Graduate School of Medicine in Japan. The study is the second that will test CYTLIMIC&#146;s cancer peptide
vaccine in combination with efti. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of cancer. Immutep is
dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3Ig</FONT>
fusion protein based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti has completed early Phase II trials as an APC activator
boosting T cell responses for cancer chemo-immunotherapy. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immutep&#146;s large
pharmaceutical partners. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep
is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For further information please visit <U>www.immutep.com</U>
or contact: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay Campbell, Vice
President of Business Development and Investor Relations, Immutep Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (917) <FONT STYLE="white-space:nowrap">860-9404;</FONT>
<U>jay.campbell@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Gregorowski, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 8234 0105;
<U>mgregorowski@citadelmagnus.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g563349g87t13.gif" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g563349g45a33.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g563349g45a33.gif
M1TE&.#=A%P-^ ,8  /___YS.K6.U>W.UA*7.K>?GY][>WN_O[_?W]];6UI24
ME+V]O<;&QJVMK:6EI;6UM9R<G&MK:W-S<\[.SGM[>XR,C(2$A-[OWH2]E(S&
ME(S&G.?W[\[GUH3&E)3&G/?_]X2]C+W>QJW6M6.M<VNU>^?OY\;>QEJM<W.]
MA._W]Z76M6.U<YS.I93&I=;GUF-C8VNUA.?WY\;>SGN]C+W>SM;OWK76O>_W
M[Z7.I<;GSI3.I=[OY];OUL[GSK7>O??W[W.]C(R]E*W6O7N]E'N]A'.U>V.M
M>Z76K;7>QG.UC*7.M?__]VN]A*W.M=[GWIS&G%JU<YS&I;76M??__[76QL;G
MQH3&G%JM:VNM>P
M
M                                                 "P     %P-^
M   '_H  @H.$A8:'B(F*BXR-CH^0D9*3E)66EYB9FIN<G9Z?H*&BHZ2EIJ>H
MJ:JKK*VNK["QLK.TM;:WN+FZN[R]OK_ P<+#Q,7&Q\C)RLO,S<[/T-'2T]35
MUM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_  ,*
M'$BPH,&#"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J
M7,FRI<N7,&/*G$FSYK8/,2Y<B/'!IL^?0&-Q"#!C  P2 V:PX!"TJ=.GG6*T
MP"* !(RK1P48T; #JM>O8!5Q&+ "QH"S, 1@%7!% -.P_G#C.JU!PNI9HP-8
MZ#BJ@8H5(R[D"AXL,\4,M7?Q]JA" D1/ $,&W"!,N3)*)6J3V#TZ@D4' 1H&
ML3A!P++ITQYO#"!AX@8+JXT)F!AP0@: #QQ06-V NK=OBB%6#.BI&D:.*8(N
M^#"1H:C9%51^2Y^^D$55%B9LA"AA:(:1JV=)Z*!.OKS #$A)K#@1X) *I'=)
M8#!/OSZ^#S/@KQYO*(2 Q/+9)^" \&"@'PD>'&+#"@?.1^"#$)JC@WYF<5>(
M"VB914)H$79(T00/)("2%,*9M1J'@BQA@P?;M8"4 ")X*"-$$$1@XP,G75"7
MB5:Y((,,(60@ !11E.#B437,_JCD0@9$0 $%$E!PP$DM_&?4##X\,8( 586'
M%VA+AHE0 E$^*4$!ZAQ@  ,-B'C+!4>1D$$)*6B@7X:KD>"$F'P25( $@$90
M 0+I* "E!"\LD L21B"(P \>W'D7#"/8T.>E DU0 04*&) . A:4*0$#NBQ(
M @LL@(<6$ZL9T02FL 9$J#J@BDJJ+C(P<<(()J)%PG\AQ"ILG[6:>:LN-ZB0
MWPH"K,#@#"KP-NRT2Q8+Y;&[(,!#"$)HQ\-CU(9;T <W;!##!C<LD4BY-_P@
M"0+EGCL9(DN4N\&LHE@; ;:1J%E  ?@Z@L !!!\0L+@(#U0" 4<<08 *\PZR
M 0=(_@20 09%G94$!@$$-H@+1W20\0P8*'%!(A_LT(,(.HB<<5(9B& A  C(
MP ((*)PU@P8V2'O( PT$[8"GARS@@- 3$&*M! H$[70##BB:B $-; HH!19
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M4A7P'&6 O[I>GMY&L^Z-ZGOA"UV9S$2[""C $ 6 DNU*QSXTO6^#KJM=ZR)
M/_NYL!WXP\O^!-&_#&D@ "*P@0@T@)CX"$ I0A ""U83GR$(#@ )Q L1/$
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M.SB%#]!J1N.$GR2#A# !40,T4X( #C KWI>"4$)X+-B&\?:"3%A*8LAHYU<
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&KI@0"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g563349g87t13.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g563349g87t13.gif
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J7\Z\N?/GT*-+GTZ]NO7KV+-KW\Z]NW?L#!8H2(#@@($"! 8(^.L@"  [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
